Drug Screening Industry Size

The report "Drug Screening Market by Offering (On-site Testing, Rapid Testing (Urine, Oral), Analytical (Breathalyzer, Immunoassay, Chromatography)), Sample (Blood, Urine, Hair), Drug (Cannabis, Alcohol), End User (Workplace, Law, Hospitals) - Global Forecast to 2030" is projected to grow from USD 10.36  billion in 2025 and to reach USD 21.29 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 15.5% during the forecast period.

Browse 531 market data Tables and 54 Figures spread through 457 Pages and in-depth TOC on"Drug Screening Market by Offering (On-site Testing, Rapid Testing (Urine, Oral), Analytical (Breathalyzer, Immunoassay, Chromatography)), Sample (Blood, Urine, Hair), Drug (Cannabis, Alcohol), End User (Workplace, Law, Hospitals) - Global Forecast to 2030" 
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/drug-alcohol-screening-market-162987773.html

The market for drug testing is being driven by the structural changes in the use of substances globally, particularly polysubstance use and pharmaceutical abuse, which are essentially expanding the scope of testing. Evidence from population-level studies has shown that people do not use substances singly; instead, the use of a combination of opioids, sedatives, stimulants, and alcohol has become the norm. In Australia, according to the 2022–2023 National Drug Strategy Household Survey (NDSHS), an estimated 10.2 million (47%) people aged 14 and over in Australia had illicitly used a drug at some point in their lifetime (including the non-medical use of pharmaceuticals), and an estimated 3.9 million (18%) had used an illicit drug in the previous 12 months. This was similar to proportions in 2019 (43% and 16%, respectively) but has increased since 2007 (38% and 13%, respectively). Similarly, according to an article by Osong Public Health Res Perspect, the prevalence of substance use among school-going children in Arab and African countries revealed that tobacco was the most commonly used substance, with a prevalence of 16%. This was closely followed by alcohol, which had a prevalence of 15%, stimulants at 11.4%, khat at 10%, and cannabis at 8%. Notably, alcohol was the only substance that showed an increasing trend in prevalence from before to after 2019, rising from 13.3% to 17%. Rising lifetime and recent drug use in developed markets and the diversification of substance use across emerging regions are structurally expanding the need for comprehensive, multi-analyte drug testing solutions, directly supporting sustained growth in laboratory and clinical toxicology markets worldwide.

The oral fluid segment is expected to register the fastest growth in the drug screening market during the forecast period.

By sample type, the oral fluid segment is expected to grow rapidly during the forecast period,  driven by its growing relevance in workplace safety, roadside testing, and post-incident investigations. Employers, law enforcement agencies, and healthcare providers are increasingly adopting on-site, non-invasive oral fluid testing because it enables directly observed sample collection, minimizes adulteration and substitution risks, and avoids the privacy and logistical challenges commonly associated with urine testing.  This trend is supported by real-world workplace data. In 2023, a study of almost 23,900 urine and oral fluid drug tests from Swedish workplaces showed that 4.6% of samples returned positive for controlled substances, with the highest positivity rates being found in samples related to accidents, incidents, or suspicion-based testing, exactly the type of scenario in which recent drug use and impairment testing are most relevant. Also, random testing and pre-employment screening comprised the vast majority of samples, and the construction industry had the highest rate of positive random tests, which points to the increasing use of oral fluid testing in safety-sensitive environments. Cannabis and stimulants were the most prevalent substances detected, which corresponds to the advantages of oral fluid testing in detecting recent illicit drug use.

In addition to the workplace, the increasing use of oral fluid testing is also supported by sports anti-doping programs, in which the World Anti-Doping Agency reported almost 239,000 tests in 2023 in Olympic sports, which marked a record level of testing and a gradual transition towards specimen types that are more difficult to cheat and more suitable for observed collections.

The lab testing services segment held the largest share of the drug screening market in 2024.

The growing need for laboratory-based drug testing is being fueled by two converging realities: the rising prevalence of polydrug use and the limitations of initial screening tests. A scale-wide analysis of over 4 million patients who tested positive for fentanyl revealed that 93% of patients had co-administered at least one other drug, underlining that single-drug or targeted screening is no longer sufficient in real-world testing scenarios. Correspondingly, behavioral data from a 2024 study revealed that 87% of music festival attendees had the intention to use drugs, with polydrug use found to be the most prevalent use pattern rather than the exception, underlining the need for comprehensive multi-drug detection capabilities rather than single drug testing.

Simultaneously, accuracy concerns in rapid screening technologies are fueling the need for laboratory confirmation. Immunoassay screening test cross-reactivity is still a problem for false positives in 5-10% of initial test results, while overall screening test accuracy in employment and compliance testing is still between 85-95%. In contrast, laboratory-based confirmatory testing with GC-MS and LC-MS/MS analyzers boasts up to 99.9% analytical accuracy, making them essential for the generation of legally defensible test results in employment testing, forensic analysis, and clinical toxicology applications.

North America registered the largest share in the global drug screening market in 2024.

North America accounted for the largest share of the global drug screening market in 2024, owing to the large number of tests being conducted in the context of workplace safety initiatives, clinical toxicology labs, and law enforcement agencies. The US continues to be a bright spot for the industry because of its opioid epidemic and increasing incidence of polysubstance use, with the DEA’s 2024 National Drug Threat Assessment confirming that synthetic opioids, particularly fentanyl, continue to dominate drug threats. Fentanyl and other synthetic opioids are implicated in about 70% of US drug-related deaths, and ongoing polydrug combinations are increasingly reported in forensic submissions. At the same time, there is a large established population of safety-sensitive industries in the US that are mandated to conduct pre-employment, random, post-incident, and return-to-duty testing, thereby fueling the need for regular testing.

Don’t miss out on business opportunities in Drug Screening Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/